1619982-95-4

Upstream product

• 1000009-66-4 (1S,2R,4aS,8aS)-1-[hydroxy(3-methoxy-5-methylphenyl)methyl]-2,5,5,8a-tetramethyldecahydronaphthalen-2-ol 
• 1619982-79-4 [(1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl](3-methoxy-5-methylphenyl)methanone 
• 1619982-78-3 (1R,2R,4aS,8aS)-1-[(3-methoxy-5-methylphenyl)carbonyl]-2,5,5,8a-tetramethyldecahydronaphthalen-2-ol 
• 1619982-84-1 (3S,4S,4aS,8aS)-4-[(3-hydroxy-5-methylphenyl)carbonyl]-3,4a,8,8-tetramethyldecahydronaphthalen-2-one 
• 1619982-83-0 (3R,4S,4aS,8aS)-4-[(3-methoxy-5-methylphenyl)carbonyl]-3,4a,8,8-tetramethyldecahydronaphthalen-2-one 
• 1619982-82-9 (2R,3R,4S,4aS,8aS)-4-[(3-methoxy-5-methylphenyl)carbonyl]-3,4a,8,8-tetramethyldecahydronaphthalen-2-ol 

Relevant academic research and scientific papers

SHIP1 MODULATORS AND METHODS RELATED THERETO

Compounds of formula (I): [Formula should be inserted here]; where [Formula should be inserted here], n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.